Skip to content

Intervention of ischemic stroke with cerebral lobe microhemorrhag with Hengqing III formula: a randomized double-blind parallel-group placebo-controlled trial

Intervention of ischemic stroke with cerebral lobe microhemorrhag with Hengqing III formula: a randomized double-blind parallel-group placebo-controlled trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026399
Enrollment
Unknown
Registered
2019-10-08
Start date
2019-11-01
Completion date
Unknown
Last updated
2019-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemic stroke with cerebral lobe microhemorrhag

Interventions

experimental group:Hengqing III formula
control group 1:Ginaton

Sponsors

Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) aged between 40 and 75 years; (2) meet the diagnostic criteria for ischemic stroke; (3) meet the diagnostic criteria for cerebral microhemorrhage; (4) patients within 14 days to 6 months after the first onset; (5) at least one risk factor for stroke that can be intervened (such as hypertension, diabetes, heart disease, hyperlipidemia, smoking, etc.); (6) sign informed consent.

Exclusion criteria

Exclusion criteria: (1) confirmed cerebral infarction caused by intracranial tumor, trauma, atrial fibrillation, etc.; (2) patients with major diseases, such as tumors, mental diseases, serious infections, diseases of the blood system, etc. (3) patients with severe functional insufficiency or impairment of important organs; (4) those who are considered to be allergic to the drugs used in this test after preliminary evaluation; (5) patients whose blood pressure and blood glucose are difficult to control to the ideal range or whose vital signs are unstable or whose physical conditions are poor; (6) those who cannot take medicine on time due to other reasons; (7) pregnant and lactating women; (8) participating in other clinical trials; (9) the researchers concluded that other reasons were not appropriate for clinical trials.

Design outcomes

Primary

MeasureTime frame
neurological deficit score;Degree of cerebral microhemorrhage;

Secondary

MeasureTime frame
Activity of Daily Living score;

Countries

China

Contacts

Public ContactMeng Shengxi

Shanghai Sixth People's Hospital

mengsx163@163.com+86 18930170565

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026